OSUR OraSure Technologies Inc.

OraSure to Participate in Upcoming Investor Conference

OraSure to Participate in Upcoming Investor Conference

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:

  • Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET

A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at . The webcast will be archived on OraSure’s website and will be available for approximately 90 days.

About OraSure Technologies, Inc. 

OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit .                                           

Investor Contact:

Jason Plagman 

VP, Investor Relations



Media Contact:

Amy Koch

Director, Corporate Communications



EN
18/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

Orasure Technologies Inc: 4 directors

Four Directors at Orasure Technologies Inc bought 197,284 shares at between 3.060USD and 3.173USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OraSure Reports Fourth Quarter 2024 Financial Results

OraSure Reports Fourth Quarter 2024 Financial Results BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. “Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by eleva...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch